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Polyglutamine (polyQ) diseases are inherited neurodegenerative 
conditions caused by expansion of a coding trinucleotide CAG repeat, 
which is translated into an abnormally long polyQ tract in the mutant 
protein.1 There are currently 9 known polyQ diseases: Huntington 
disease (HD), dentatorubral-pallidoluysian atrophy (DRPLA), spinal 
bulbar muscular atrophy (SBMA) and 6 spinocerebellar ataxias 
(SCA 1, 2, 3, 6, 7 and 17). The molecular diagnostics laboratory of 
the National Health Laboratory Service in Cape Town is the only 
centre in South Africa offering diagnostic testing for the polyQ 
SCAs, and works in close collaboration with the Division of Human 
Genetics at the University of Cape Town (UCT) to provide patients 
with the opportunity to participate in ground-breaking research into 
pathogenesis and treatment.
Despite genetic and clinical heterogeneity, the presence of a 
common mutation suggested that a common pathogenic mechanism 
must link all 9 diseases. However, emerging evidence indicates that 
polyQ pathogenesis is more complex (Fig. 1). Here we summarise 
theories of pathogenesis and discuss how this knowledge underpins 
the development of novel therapeutic strategies.
PolyQ disease pathogenesis mechanisms
Aggregation and impairment of proteasome clearance
Early studies of polyQ disease revealed large nuclear inclusion bodies 
containing proteolytically cleaved mutant protein as a common 
pathogenic marker. These aggregates recruit nuclear proteins, in 
addition to proteins containing polyQ tracts. They are marked for 
ubiquitin proteasome degradation but for unknown reasons are not 
degraded.This suggests that the structure of the aggregates renders 
them resistant to the misfolded protein clearance pathway, leading to 
cellular dysfunction.2 This theory could account for the susceptibility 
of neurons associated with all 9 disorders, since these highly 
metabolically active cells may be more sensitive to perturbations in 
cellular machinery.
Further investigations – including the observation that their 
formation does not entirely correlate with neuronal susceptibility 
– have contradicted the theory of inclusion body toxicity, with 
increasing evidence suggesting that they might instead serve a 
protective role within cells. It is now generally accepted that the 
toxic species are smaller, less visible micro-aggregates. Nevertheless, 
inclusions remain a hallmark of polyQ disease pathogenesis.
Autophagy
Impairment of autophagy, the process by which the cell recycles 
intracellular components, has been implicated in polyQ disorders.3 
Although the mechanism is unclear, upregulation of autophagy 
alleviates cytotoxicity in models of polyQ disease. This provides a 
common theory of polyQ pathogenesis since loss of autophagy causes 
general neurodegeneration in mice.4 However, all studies to date have 
been performed in models over-expressing the mutant protein, and 
therefore studies in more representative models of polyQ disease are 
crucial.
Protein-protein interactions/post-translational mechanisms
The expanded polyQ tract imparts a conformational change to the 
mutant protein and therefore directly affects interactions with its native 
binding partners. In addition, post-translational modifications such as 
phosphorylation, SUMOylation and acetylation of specific residues in 
several polyQ proteins can be altered in the presence of the mutation, 
affecting interactions with their natural binding proteins. Importantly, 
direct inhibition of these post-translational alterations reduces mutant 
protein toxicity (reviewed by La Spada and Taylor5).
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arising from expanded trinucleotide CAG repeats in the disease-
causing gene, which are translated into polyglutamine tracts in 
the resultant protein. Although these diseases share a common 
type of mutation, emerging evidence suggests that pathogenesis is 
complex, involving disruption of key cellular pathways, and varying 
with the disease context.
An understanding of polyglutamine disease mechanisms is 
critical for development of novel therapeutics. Here we summarise 
theories of molecular pathogenesis, and examine ways in which 
this knowledge is being harnessed for therapy, with reference to 
work under way at the University of Cape Town. Despite a plethora 
of preclinical data, clinical trials of therapies for polyglutamine 
diseases have had only limited success. However, recently initiated 
trials, including those using gene silencing approaches, should 
provide valuable insights into the safety and efficacy of therapies 
directly targeting polyglutamine pathogenesis. This is particularly 
relevant in the South African context, where the frequencies of 2 
polyglutamine diseases, spinocerebellar ataxia types 1 and 7, are 
among the highest globally.
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Transcriptional alterations
Many polyQ proteins function in transcriptional regulation,6 and 
several reports have identified transcriptional changes in molecular 
chaperones and genes involved in neuronal differentiation, often 
observed prior to cellular dysfunction. However, studies have not 
revealed a common subset of dysregulated transcripts. How then do 
the polyQ proteins confer transcriptional alterations if not through 
the shared mutation? A possible answer is that transcriptional 
effects depend on the cellular context of the mutant polyQ 
protein. Each native protein has distinct regulatory mechanisms in 
different neuronal sub-types; thus, the mutation is likely to lead to 
transcriptional dysregulation in the neuronal subset most susceptible 
to changes in that protein. One mechanism for this change may be 
chromatin modification. If chromatin architecture is unique to each 
neuronal subset they may be differentially susceptible to mutations 
in each polyQ protein.6
Loss of function and additional pathogenic mechanisms
Although polyQ diseases are caused by a toxic gain-of-function of 
the mutant protein, it is likely that loss of function also contributes 
to pathogenesis, since knockout models of polyQ disease show 
neurodegeneration and polyQ inclusions recruit the native protein, 
impairing its normal function. Thus, understanding normal protein 
function is critical in understanding disease pathogenesis. A number 
of additional disease mechanisms have been proposed including 
mitochondrial dysfunction, enhanced apoptosis and excitotoxicity 
caused by glutamate receptor overactivation.
Given the multitude of cellular insults triggered by expanded 
polyQ tracts, developing an effective therapy appears a daunting 
prospect. However, based on current theories of pathogenesis, several 
proof-of-principle treatments have already been demonstrated.
Therapeutic strategies
Historically, treatment for polyQ diseases has focused on symptomatic 
management, rather than disease modification. Understanding the 
molecular mechanisms of pathogenesis offers the opportunity to 
prevent or delay disease symptom onset, through the identification of 
targets within the disease pathway which may be amenable to therapy 
(Fig. 1). Experimental therapies fall into 2 categories – those aimed 
at removing the burden of accumulated mutant protein and those 
targeting downstream effects of the mutant protein.
Therapies targeting polyglutamine proteins
Gene silencing
Given the complexities of polyQ pathogenesis, one logical approach 
is to suppress production of the mutant protein upstream of its 
deleterious effects. Further, silencing the mutant gene, while 
retaining wild-type expression may be of therapeutic benefit. This 
has led to the development of gene silencing therapies, using 
either RNA interference (RNAi) or antisense oligonucleotide (AON) 
approaches. Both have shown promise in studies in animal models 
of polyQ diseases, including SBMA, SCA1, and HD – rescuing 
toxicity, preventing apoptosis, and allowing for the development 
of sophisticated delivery mechanisms.7 Researchers at UCT, in 
collaboration with the Universities of Oxford and the Witwatersrand, 
were the first to demonstrate the potential for RNAi-based gene 
silencing in the South African SCA7 population. However, a number 
of challenges must be addressed before these results can be translated 
to the clinic.
Evidence from knockout animal models suggests that several 
polyQ genes are critical in development and central nervous system 
(CNS) function and therefore that allele-specific therapies may be 
required. This approach, which relies on the presence of targetable 
sequence differences in order 
to discriminate between the 
normal and mutated transcripts, 
is technically challenging, and 
likely to limit eligibility for 
therapies, since it relies on single 
nucleotide polymorphisms 
(SNPs) in linkage disequilibrium 
with the polyQ expansion, or 
differences in CAG repeat 
length to accomplish sequence 
discrimination. Two recent 
studies, encouraging efforts 
to continue to develop gene 
silencing therapies for the polyQ 
diseases, indicate that non-allele-
specific approaches are better 
tolerated in HD and SCA3 mouse 
models than was originally 
thought;8,9 and that allele-specific 
silencing may provide therapy 
in a majority of European HD 
patients using relatively few 
disease-linked SNPs.10
Clearing misfolded mutant 
protein and inhibiting 
aggregate formation
Decreasing mutant protein 
levels may also be achieved 
by enhancing polyQ protein 
Fig. 1. PolyQ pathogenesis. The schematic shows a cascade of events (black arrows) affecting neurodegeneration, 
including transcriptional dysregulation from altered chromatin, proteolytic cleavage of polyQ protein, micro-aggregates 
of polyQ protein, inclusion body formation, and altered binding of normal protein interactions due to post-translational 
modifications (indicated by the red X). Autophagy is indicated as a method of cellular defence. Targets for treatment 
(shown by red markers) include inhibition of protein synthesis by silencing RNA, restoring chromatin architecture by 
HDAC inhibitors, activation of molecular chaperones to reduce oligomerisation of polyQ proteins, and upregulation (red 
arrow) of autophagy.
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clearance, through upregulation of the two main cellular pathways 
responsible for degradation of misfolded proteins – the ubiquitin-
proteasome system (UPS) and autophagy. While impairment of the 
UPS has been observed in several polyQ diseases, upregulation of 
this pathway is technically challenging and attention has therefore 
shifted to enhancing autophagy. Activation of autophagy using the 
mTOR inhibitor rapamycin has been shown to reduce mutant protein 
toxicity in models of HD and SCA3, suggesting that small molecules 
capable of inducing the autophagic cascade may be of therapeutic 
benefit.11,12
Another approach to clear mutant polyQ proteins is via molecular 
chaperones capable of promoting refolding of misfolded proteins. 
Overexpression of heat shock proteins Hsp27 and Hsp104 suppresses 
neurotoxicity in HD models.13 However, global induction of the heat 
shock response (HSR) is of only transient benefit, suggesting that 
impairment of the HSR may occur during polyQ disease progression.14 
These findings motivate for the development of combinatorial 
therapies such as histone deacetylase (HDAC) inhibitors capable of 
enhancing HSR gene transcription.
Direct methods of preventing polyQ protein aggregation using 
molecules such as Congo Red and cystamine, which act to stabilise 
the native non-toxic conformation of the protein, prevent cross-
linking of the mutant isoform, or promote clearance from the cell, 
have also been attempted. All have demonstrated some therapeutic 
benefit but efficacy and delivery remain to be optimised.15
Therapies targeting downstream effects of polyQ proteins
Transcriptional dysregulation
The inhibition of HDACs, repressors of transcription, has been 
proposed as a method for mitigating transcriptional dysregulation. A 
variety of small-molecule HDAC inhibitors have been tested as anti-
cancer drugs and several have been shown to rescue polyQ disease 
phenotypes.16 In particular, the discovery that HD mice, engineered 
to be deficient in HDAC4, show a phenotypic improvement suggests 
that this may be a promising therapeutic approach.
Upregulation of specific genes known to have a neuroprotective 
role (e.g. brain derived neurotrophic factor) has also shown beneficial 
effects. However, this requires a thorough understanding of the 
functions of downstream targets of transcriptional regulation by 
polyQ proteins, in order to identify the most promising therapeutic 
targets.
Additional therapeutic approaches
A number of additional therapeutic approaches have been proposed, 
which aim to reverse the downstream cellular effects of mutant 
polyQ proteins. These include compounds capable of alleviating 
energy metabolism defects or mitigating oxidative stress. Riluzole 
and remacemide, which mitigate excitotoxicity, have achieved 
some success in HD mice, although these results have not been 
successfully reproduced in clinical trials.17 Anti-apoptotic drugs such 
as minocycline and caspase inhibitors have also shown promise in 
polyQ animal models, although data from long-term studies will 
be required in order to rule out possible side-effects associated with 
suppression of these key cellular pathways.
Clinical considerations
Despite the plethora of preclinical investigations, few have progressed 
to clinical trials. The low incidence, late onset, slow progression and 
clinical heterogeneity of polyQ diseases make demonstration of 
clinical efficacy particularly difficult.
A number of major technical issues remain to be addressed, 
including questions of dosage and delivery – particularly pertinent 
in CNS conditions, which require delivery across the blood-brain 
barrier, and rapid attenuation in the event of adverse effects. There 
are also more challenging tasks – designing therapies which treat the 
maximum number of patients, without compromising  on off-target 
effects, immunogenicity or allele specificity (in the case of gene 
silencing); and balancing the benefits of relatively broad-spectrum 
therapeutics (such as HSR induction or RNAi) with their potential to 
disrupt normal cellular processes.
Nonetheless, the recent progress of RNAi to the clinic suggests 
that effective therapies for polyQ diseases may be within reach. At 
the time of writing, 14 clinical trials involving RNAi are ongoing, 
although none yet involve the CNS.18 AONs are also being tested 
in trials for Duchenne muscular dystrophy and cancer (http://
www.clinicaltrials.gov), and the first clinical study of AONs in 
neurodegenerative disease has been initiated.19
Several therapies designed to target additional polyQ pathogenic 
mechanisms, including mitigators of exicitotoxicity, UPS activators, 
anti-apoptotics, and modulators of transcriptional activity, are 
undergoing clinical trials (http://www.clinicaltrials.gov). SBMA, 
unique among the polyQ diseases by virtue of its X-linked mode of 
inheritance, is also the target of novel therapeutic strategies involving 
androgen deprivation, but with limited efficacy to date.
Results from these trials should provide valuable insight into 
how to safely and effectively deliver therapies to the human CNS. 
However, critical to success will be the generation of more accurate 
in vitro and in vivo models of disease (see below).
The South African context
The development of effective therapies for polyQ diseases is 
particularly relevant to South Africa, where the frequencies of SCA1 
and SCA7 are among the highest globally.20 Researchers at UCT have 
previously reported founder effects in the mixed-ancestry population 
(SCA121 and HD22)  and the indigenous black African population 
(SCA723), with further research ongoing into the HD founder 
haplotypes. This phenomenon offers the ideal genetic background 
for the development of allele-specific gene-silencing-based therapies 
in South Africa, allowing patients to be treated by targeting a single 
disease-linked SNP.24
The neurodegenerative disorders research team at the UCT Division 
of Human Genetics, in collaboration the University of Oxford, has 
recently established a ground-breaking new disease model for SCA7 
using patient-derived cells to generate induced pluripotent stem cells 
(iPSCs). This offers the first human disease cell model to test and 
refine the novel therapies developed in the UCT laboratory.
Conclusion
The identification of a common pathogenic mutation underlying the 
clinically and genetically heterogeneous polyQ diseases suggested 
initially that common therapies could be easily designed. The reality 
is vastly different. As the molecular basis of polyQ diseases is revealed 
in ever-increasing complexity, it is clear that the task of developing 
therapies is not straightforward. Nevertheless, the identification of 
numerous therapeutic targets and development of a human cell-
based model of disease, offers the potential to develop effective 
treatments for polyQ diseases.
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